# Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices

> **NCT01012739** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 35 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Indacaterol 150 μg via the Concept1 dry-powder inhaler
- **DRUG:** Indacaterol 60 μg via the Simoon dry-powder inhaler
- **DRUG:** Indacaterol 120 μg via the Simoon dry-powder inhaler
- **DRUG:** Placebo to indacaterol via the Concept1 dry-powder inhaler

## Key facts

- **NCT ID:** NCT01012739
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2011-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01012739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01012739, "Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT01012739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*